A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors.
Endometrial cancer
Hyaluronic acid
Non-hormonal vaginal moisturizer
Sexual function
Vaginal health
Vulvar health
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
26
03
2020
accepted:
17
05
2020
pubmed:
12
6
2020
medline:
10
4
2021
entrez:
12
6
2020
Statut:
ppublish
Résumé
To assess the efficacy of non-hormonal, hyaluronic acid (HLA)-based vaginal gel in improving vulvovaginal estrogen-deprivation symptoms in women with a history of endometrial cancer. For this single-arm, prospective, longitudinal trial, we enrolled disease-free women with a history of endometrial cancer who underwent surgery (total hysterectomy) and postoperative radiation. Participants used HLA daily for the first 2 weeks, and then 3×/week until weeks 12-14; dosage was then increased to 5×/week for non-responders. Vulvovaginal symptoms and pH were assessed at 4 time points (baseline [T1]; 4-6 weeks [T2]; 12-14 weeks [T3]; 22-24 weeks [T4]) with clinical evaluation, the Vaginal Assessment Scale (VAS), Vulvar Assessment Scale (VuAS), Female Sexual Function Index (FSFI), and Menopausal Symptom Checklist (MSCL). Of 43 patients, mean age was 59 years (range, 38-78); 54% (23/43) were partnered; and 49% (21/43) were sexually active. VAS, VuAS, MSCL, and SAQ (Sexual Activity Questionnaire) scores significantly improved from baseline to each assessment point (all p < .002). FSFI total mean scores significantly increased from T1 to T2 (p < .05) and from T1 to T4 (p < .03). At T1, 41% (16/39) felt confident about future sexual activity compared to 68% (17/25) at T4 (p = .096). Severely elevated vaginal pH (>6.5) decreased from 30% (13/43) at T1 to 19% (5/26) at T4 (p = .41). The HLA-based gel improved vulvovaginal health and sexual function of endometrial cancer survivors in perceived symptoms and clinical exam outcomes. HLA administration 1-2×/week is recommended for women in natural menopause; a 3-5×/week schedule appears more effective for symptom relief in cancer survivors.
Identifiants
pubmed: 32522420
pii: S0090-8258(20)31094-5
doi: 10.1016/j.ygyno.2020.05.025
pmc: PMC7423634
mid: NIHMS1597313
pii:
doi:
Substances chimiques
Vaginal Creams, Foams, and Jellies
0
Hyaluronic Acid
9004-61-9
Types de publication
Clinical Trial
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
366-374Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest Outside the submitted work, Dr. Jewell reports personal fees from Covidien/Medtronic. All other authors have no conflicts of interest to report.
Références
JAMA. 2006 Jun 21;295(23):2742-51
pubmed: 16754728
Cancer. 1999 Sep 1;86(5):814-20
pubmed: 10463980
Acta Oncol. 2017 May;56(5):661-666
pubmed: 28084859
Int J Community Based Nurs Midwifery. 2016 Jan;4(1):69-78
pubmed: 26793732
Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):e187-93
pubmed: 22572074
Qual Life Res. 1996 Feb;5(1):81-90
pubmed: 8901370
Support Care Cancer. 2018 Feb;26(2):643-650
pubmed: 28921241
Cancer. 2012 Sep 15;118(18):4606-18
pubmed: 22359250
J Cancer Surviv. 2017 Apr;11(2):274-283
pubmed: 27868156
Support Care Cancer. 2018 Apr;26(4):1335-1343
pubmed: 29164377
Psychooncology. 2011 Apr;20(4):378-86
pubmed: 20878833
Gynecol Oncol. 2003 May;89(2):281-7
pubmed: 12713992
Maturitas. 2003 May 30;45(1):29-38
pubmed: 12753941
Eur Rev Med Pharmacol Sci. 2008 Nov-Dec;12(6):411-6
pubmed: 19146203
Med Care. 2007 May;45(5 Suppl 1):S12-21
pubmed: 17443114
Qual Life Res. 2009 Oct;18(8):1085-93
pubmed: 19672697
J Womens Health (Larchmt). 2007 Jan-Feb;16(1):139-48
pubmed: 17324105
Brachytherapy. 2015 Jul-Aug;14(4):464-70
pubmed: 25887343
J Clin Oncol. 2015 Oct 20;33(30):3394-400
pubmed: 26215946
J Clin Oncol. 1999 Sep;17(9):2659-69
pubmed: 10561339
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Arch Gynecol Obstet. 2011 Mar;283(3):539-43
pubmed: 20135132
J Contemp Brachytherapy. 2016 Dec;8(6):512-517
pubmed: 28115957
J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208
pubmed: 10782451
J Sex Med. 2017 Jan;14(1):144-151
pubmed: 28011209
J Sex Med. 2013 Jun;10(6):1575-84
pubmed: 23574713
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1029-36
pubmed: 27371756
Med Care. 2007 May;45(5 Suppl 1):S22-31
pubmed: 17443115
Cancer. 2009 Mar 15;115(6):1142-53
pubmed: 19195044
Eur J Gynaecol Oncol. 2011;32(1):65-8
pubmed: 21446328